Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO's Richard Schilsky On State-of-the-Art Oncology Trials

ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.

Clinical Trials ImmunoOncology Scrip 100

IO Biomarkers: Where Do We Stand In 2017?

Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.

ImmunoOncology Cancer Scrip 100

A Status Check Of The Alzheimer’s Trial Landscape

Despite high-profile failures, including the recent disappointing results for Axovant Science’s Phase III MINDSET study, the trial landscape for Alzheimer’s disease remains busy.

Scrip 100 Clinical Trials Neurology

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.

Rare Diseases Innovation Market Intelligence

Advertisement
UsernamePublicRestriction

Register

Advertisement